Leap Historical Cash Flow
| LPTX Stock | USD 2.52 0.03 1.18% |
Analysis of Leap Therapeutics cash flow over time is an excellent tool to project Leap Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 68.8 M or Depreciation of 14.2 K as it is a great indicator of Leap Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Leap Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Leap Therapeutics is a good buy for the upcoming year.
Leap |
About Leap Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Leap balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Leap's non-liquid assets can be easily converted into cash.
Leap Therapeutics Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Total Cashflows From Investing Activities
The net amount of cash used in or generated from a company's investment activities, such as purchasing or selling assets, during a reporting period.Net Borrowings
The difference between the amount of new debt a company has taken on and the amount of debt it has paid off during a given period.Most accounts from Leap Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Leap Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Leap Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Leap Stock please use our How to Invest in Leap Therapeutics guide.At this time, Leap Therapeutics' Cash And Cash Equivalents Changes is fairly stable compared to the past year.
Leap Therapeutics cash flow statement Correlations
Click cells to compare fundamentals
Leap Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Leap Therapeutics cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (12.4M) | 48.2M | 62.8M | (49.4M) | 5.1M | 7.4M | |
| Stock Based Compensation | 3.9M | 2.6M | 3.5M | 5.2M | 5.1M | 3.3M | |
| Free Cash Flow | (27.0M) | (26.0M) | (35.2M) | (49.0M) | (43.8M) | (41.6M) | |
| Change In Working Capital | 1.3M | (990K) | 1.0M | (651K) | 2.5M | 2.6M | |
| Begin Period Cash Flow | 16.3M | 3.9M | 52.1M | 114.9M | 65.5M | 68.8M | |
| Other Cashflows From Financing Activities | (437K) | 25.8M | 813K | (210K) | (29K) | (27.6K) | |
| Depreciation | 47K | 34K | 29K | 16K | 15K | 14.3K | |
| Other Non Cash Items | 732K | 634K | 527K | 855K | 30.0M | 31.5M | |
| Total Cash From Operating Activities | (26.9M) | (26.0M) | (35.2M) | (49.0M) | (43.8M) | (41.6M) | |
| Net Income | (32.9M) | (27.5M) | (40.6M) | (54.6M) | (81.4M) | (77.3M) | |
| Total Cash From Financing Activities | 14.8M | 74.0M | 98.0M | (210K) | (30K) | (28.5K) | |
| End Period Cash Flow | 3.9M | 52.1M | 114.9M | 65.5M | 70.6M | 38.1M | |
| Sale Purchase Of Stock | 1M | 25.5M | 813K | 0.0 | (1K) | (950.0) | |
| Investments | (64K) | 0.0 | (85K) | 25K | 49.0M | 51.4M | |
| Change To Account Receivables | 643K | 117K | (1.2M) | (1.0M) | 1.3M | 1.4M | |
| Change To Netincome | 3.7M | 1.8M | 4.1M | 6.2M | 7.1M | 7.5M | |
| Change To Liabilities | 368K | (695K) | (1.1M) | 3.9M | 1.1M | 1.3M | |
| Change To Operating Activities | 250K | 147K | (1.4M) | (1.7M) | (1.6M) | (1.5M) | |
| Cash And Cash Equivalents Changes | (10.1M) | (12.2M) | 48.1M | 62.9M | 72.3M | 75.9M | |
| Cash Flows Other Operating | 483K | 2.9M | (275K) | (2.6M) | (2.3M) | (2.2M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Leap Stock Analysis
When running Leap Therapeutics' price analysis, check to measure Leap Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Leap Therapeutics is operating at the current time. Most of Leap Therapeutics' value examination focuses on studying past and present price action to predict the probability of Leap Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Leap Therapeutics' price. Additionally, you may evaluate how the addition of Leap Therapeutics to your portfolios can decrease your overall portfolio volatility.